In a report released today, Alex Arfaei from BMO Capital assigned a Buy rating to AstraZeneca (NYSE: AZN), with a price target of $41. The company’s shares opened today at $35.43, close to its 52-week high of $36.75.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 4.8% and a 65.3% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
AstraZeneca has an analyst consensus of Moderate Buy, with a price target consensus of $41.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.75 and a one-year low of $28.43. Currently, AstraZeneca has an average volume of 3.86M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.